Comparison of the therapeutic efficacy of pregabalin and duloxetine in peripheral neuropathy induced by taxanes containing chemotherapy regimens in women with breast cancer, a randomized clinical trial.

Mazandaran University of Medical Sciences0 个研究点目标入组 82 人开始时间: 待定最近更新: 2018年2月22日

适应症

试验速览

暂无简介。

•Age of more than 18 y; NCI Common Terminology Criteria for Adverse Events scale (NCI grade> 1); Minimum rating of NRS scale: 4 (0-10)
•Exclusion criteria:
•Having other clinical conditions that cause neuropathies, such as diabetes or trauma; Alcohol abuse; History of central nervous system diseases; History of heart, hepatic and renal failure (creatinine clearance below 60ml/min); History of glaucoma; History of depression, anxiety, bipolar, psychotic disorders and suicidal ideation; Receiving other neurotoxic chemotherapy drugs; Having concomitant use of MAOI, BZD and gabapentin; Females during pregnancy or lactation; Patients who have received pregabalin or duloxetine in recent 15 days; Having concomitant use of analgesics or effective on nerve activity drugs such as vitamin B12, lamotrigine, valproate and TCA (except pregabalin or duloxetine) will be excluded if they spent a total of 7 days washout, the patients also can be studied; Concomitant use of selected analgesics was allowed (eg, nonsteroidal anti-inflammatory drugs , acetaminophen, aspirin,..) but only patients receiving stable doses in
•the 2 weeks before randomization could participate: (1) no new analgesics were added, (2) no analgesics were discontinued and (3) the weekly 24-hour total analgesic dose did not fluctuate up or down by more than 10% in the 2weeks before study registration

发起方